Acuson sells 1000th Sequoia
Ultrasound vendor Acuson of Mountain View, CA, announced this month that it has sold its 1000th Sequoia premium scanner, which was installed at the Karolinska Hospital in Stockholm, Sweden. Acuson introduced Sequoia in 1996 (SCAN 5/8/96).In other
Ultrasound vendor Acuson of Mountain View, CA, announced this month that it has sold its 1000th Sequoia premium scanner, which was installed at the Karolinska Hospital in Stockholm, Sweden. Acuson introduced Sequoia in 1996 (SCAN 5/8/96).
In other Acuson news, the company has sold 10 ultrasound scanners to South Korea, a sign that the country's economic woes are not insurmountable for imaging vendors. Acuson sold three Sequoias and seven Aspen scanners to Je-Saeng General Hospital in Boondang.
Acuson on March 10 announced the installation of 16 Sequoia scanners at the University of California, Los Angeles and at the University of California, San Francisco. UCLA is acquiring nine Sequoias and one Aspen scanner, while UCSF has installed seven Sequoias.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
